Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels



      We evaluated the effect of micro-coated fenofibrate on lipid parameters, high sensitivity C-reactive protein and paraoxonase1 levels in dyslipidemic patients with low high-density lipoproteins levels. In addition, the effects of the paraoxonase1 polymorphisms on lipid and paraoxonase1 responses to fenofibrate therapy were examined.


      A total of 61 dyslipidemic patients with low high-density lipoproteins levels were recruited into this study to receive micro-coated fenofibrate (160 mg/day) for 12 weeks. Lipid parameters, C-reactive protein, paraoxonase1 concentration and activity were measured at baseline and after 6 and 12 weeks of fenofibrate treatment. Four polymorphisms in both the coding (L55M and Q192R) and regulatory regions (T-108C and G-909C) of human paraoxonase1 were also quantified.


      Micro-coated fenofibrate significantly decreased total cholesterol, triglycerides, non-high-density lipoprotein cholesterol, oxidized low-density lipoprotein and apolipoprotein-B levels after 6 and 12 weeks (all p < 0.001). While high-density lipoprotein and apolipoprotein AI levels were significantly increased by 14.7% and 6.9%, respectively, after 6 weeks and by 17.3% and 7.2%, respectively, after 12 weeks (all p < 0.01). There were no significant differences in the mean of low-density lipoprotein and C-reactive protein after fenofibrate treatment. There were significant increases in paraoxonase1 concentration and activity by 7.7% and 5.7% after 6 weeks and by 14.6% and 10.1% after 12 weeks, respectively (all p < 0.01). After micro-coated fenofibrate therapy, a significantly positive correlation between the change in high-density lipoprotein and the changes in paraoxonase1 concentration and activity was observed (p = 0.001). On the other hand, the changes in paraoxonase1 activity were significantly and negatively correlated with the changes in triglycerides (p = 0.007). The therapeutic response of lipid parameters to micro-coated fenofibrate was independent of paraoxonase1 polymorphisms. However, paraoxonase1 Q192R and T-108C polymorphisms significantly affected the increase in paraoxonase1 activity (the highest increase in 192QQ and −108TT) and paraoxonase1 concentration (the highest increase in −108TT).


      Lipid-modifying therapy with micro-coated fenofibrate in patients with low high-density lipoprotein levels not only reduced atherogenic lipids (total cholesterol, triglycerides, oxidized low-density lipoprotein and apolipoprotein-B) and increased atheroprotective lipids but also increased paraoxonase1 concentration and activity. Increasing paraoxonase1 levels by fenofibrate may play an important role in decreasing low-density lipoprotein oxidation.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Franzen J.
        • Johansson B.
        • Gustfson A.
        Reduced high-density lipoproteins as a risk factor after acute myocardial infarction.
        Acta Med Scand. 1987; 221: 357-362
        • Gordon D.
        • Rifkind B.
        Current concepts: high-density lipoproteins—the clinical implications of recent studies.
        N Engl J Med. 1989; 321: 1311-1315
        • Young C.
        • Karas R.
        • Kuvin J.
        High-density lipoprotein cholesterol and coronary heart disease.
        Cardiol Rev. 2004; 12: 107-119
        • Hersberger M.
        • vonEckardstein A.
        Low high-density lipoprotein cholesterol physiological background, clinical importance and drug treatment.
        Drugs. 2003; 63: 1907-1945
        • Mackness M.
        • Arrol S.
        • Durrington P.
        Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein.
        FEBS Lett. 1991; 286: 152-154
        • Mackness M.
        • Arrol S.
        • Abbott C.
        • Durrington P.
        Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase.
        Atherosclerosis. 1993; 104: 129-135
        • Watson A.
        • Berliner J.
        • Hama S.
        • et al.
        Protective effect of high-density lipoprotein associated paraoxonase inhibition of the biological activity of minimally oxidized low-density lipoprotein.
        J Clin Invest. 1995; 96: 2882-2891
        • Aviram M.
        • Hardak E.
        • Vaya J.
        • et al.
        Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions PON1 esterase and peroxidase-like activities.
        Circulation. 2000; 101: 2510-2517
        • Humbert R.
        • Adler D.
        • Distecke C.
        • et al.
        The molecular basis of the human serum paraoxonase activity polymorphism.
        Nat Genet. 1993; 3: 73-76
        • Costa L.
        • Vitalone A.
        • Cole T.
        • Furlong C.
        Modulation of paraoxonase (PON1) activity.
        Biochem Pharmacol. 2004; : 1-10
        • Deakin S.
        • James R.
        Genetic and environmental factors modulating serum concentrations and activities of the anti-oxidant enzyme paraoxonase 1.
        Clin Sci. 2004; 107: 435-447
        • Ayub A.
        • Mackness M.
        • Arrol S.
        • et al.
        Serum paraoxonase after myocardial infarction.
        Arterioscler Thromb Vasc Biol. 1999; 19: 330-335
        • Mackness M.
        • Harty D.
        • Bhatnager D.
        • et al.
        Serum paraoxonase activity in familial hypercholesterlaemia and insulin-dependent diabetes mellitus.
        Atherosclerosis. 1991; 86: 193-199
        • Mackness B.
        • Durrington P.
        • Abuashia B.
        • Boulton A.M.
        • Mackness M.
        Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy.
        Clin Sci. 2000; 98: 355-363
        • Mackness B.
        • Durrington P.
        • McElduff P.
        • et al.
        Low paraoxonase activity predicts coronary events in the caerphilly prospective study.
        Circulation. 2003; 107: 2775-2779
        • Rubins H.
        • Robin S.
        • Collins D.
        Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: veterans affairs high-density Lipoprotein Intervention Trial Study Group.
        N Engl J Med. 1999; 341: 410-418
      1. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the diabetes atherosclerosis intervention study, a randomised study.
        Lancet. 2001; 357: 905-910
        • Fruchart J.
        Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism.
        Am J Cardiol. 2001; 88: 24N-29N
        • Guichard J.
        • Blouquin P.
        • Quing Y.
        A new formulation of fenofibrate: suprabioavailable tablets.
        Curr Med Res Opin. 2000; 16: 134-138
        • Abbott C.A.
        • Mackness M.I.
        • Kumar S.
        • Boulton A.J.M.
        • Durrington P.N.
        Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins.
        Arterioscler Thromb Vasc Biol. 1995; 15: 1812-1818
        • Mackness B.
        • Mackness M.
        • Arrol S.
        • Turkie W.
        • Durrington P.
        Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon.
        Br J Pharmacol. 1997; 1997: 265-268
        • Brophy V.
        • Jampsa R.
        • Clendenning J.
        • et al.
        Effects of 5′ regulatory region polymorphisms on paraoxonase-gene (PON1) expression.
        Am J Hum Genet. 2001; 68: 1428-1436
        • Mackness B.
        • Mackness M.
        • Arrol S.
        • et al.
        Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus.
        Atherosclerosis. 1998; 139: 341-349
      2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).
        JAMA. 2001; 285: 2486-2497
        • Despres J.
        Increasing high-density lipoprotein cholesterol: an update on fenofibrate.
        Am J Cardiol. 2001; 88: 30N-36N
        • Melenovosky V.
        • Malik J.
        • Wichterle D.
        • et al.
        Comparison of the effects of atorvastatin or fenofibrate on non-lipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.
        Am Heart J. 2002; 144: G1-G8
        • Wang T.
        • Chen W.
        • Lin J.
        • et al.
        Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles.
        Atherosclerosis. 2003; 170: 315-323
        • Koh K.
        • Ahn J.
        • Han S.
        • et al.
        Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis.
        Atherosclerosis. 2004; 174: 379-383
        • Tomas M.
        • Senti M.
        • Garcia-Faria F.
        Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients.
        Arterioscler Thromb Vasc Biol. 2000; 20: 2113-2119
        • Paragh G.
        • Balogh Z.
        • Seres I.
        Effect of gemfibrozil on HDL-associated serum paraoxonase activity and lipoprotein profile in patient with hyperlipidaemia.
        Clin Drug Invest. 2000; 19: 277-282
        • Paragh G.
        • Seres I.
        • Harangi M.
        • et al.
        The effects of micronized fenofibrate on paraoxonase activity in patients with coronary heart disease.
        Diab Metab. 2003; 29: 613-618
        • Durrington P.
        • Mackness M.
        • Bhatnager D.
        Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer protein, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
        Atherosclerosis. 1998; 138: 217-225
        • Turay M.
        • Gmiakova V.
        • Valka J.
        Changes in paraoxonase and apolipoprotein A-I, B, CIII and E in subjects with combined familial hyperlipoproteinaemia treated with ciprofibrate.
        Drugs Exp Clin Res. 2002; 26: 83-88
        • Gouedard C.
        • Koum-besson N.
        • Barouki R.
        • Morel Y.
        Opposite regulation of the human paraoxonase 1 gene PON1 by fenofibrate and statins.
        Mol Pharmacol. 2003; 63: 945-956
        • Adkins S.
        • Gan K.
        • Mody M.
        • LaDu B.
        Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes.
        Am J Hum Genet. 1993; 52: 598-608
        • Suehiro T.
        • Nakamura T.
        • Inoue M.
        • et al.
        A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression.
        Atherosclerosis. 2000; 150: 295-298
        • Odawara M.
        • Tachi Y.
        • Yamashita K.
        Paraoxonase polymorphism (Gln192-Arg) is associated with coronary heart disease in Japanese non-insulin-dependent diabetes mellitus.
        J Clin Endocrinol Metab. 1997; 82: 2257-2260
        • Zama T.
        • Murata M.
        • Matsubara Y.
        • et al.
        A 192Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese.
        Arterioscler Thromb Vasc Biol. 1997; 17: 3565-3569
        • Herrmann S.
        • Blanc H.
        • Poirier O.
        • et al.
        The Gln/Arg polymorphism of human paraoxonase (PON192) is not related to myocardial infarction in the ECTIM Study.
        Atherosclerosis. 1996; 126: 299-303
        • Saha N.
        • Roy A.
        • Teo S.
        • Tay J.
        • Ratnam S.
        Influence of serum paraoxonase polymorphism on serum lipids and lipoproteins.
        Clin Genet. 1991; 40: 277-282
        • Hegele R.
        • Brunt J.
        • Connelly P.
        A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate.
        Arterioscler Thromb Vasc Biol. 1995; 15: 89-95
        • Malin R.
        • Laaksonen R.
        • Knuuti J.
        • et al.
        Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol.
        Pharmacogenetics. 2001; 11: 625-633